Drug Combination Details
| General Information of the Combination (ID: C12647) | |||||
|---|---|---|---|---|---|
| Name | Tanshinone IIA NP Info | + | Nutlin-3 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SUP-B15 | CVCL_0103 | B acute lymphoblastic leukemia | Homo sapiens | ||
| NALM-6 | CVCL_0092 | Adult B acute lymphoblastic leukemia | Homo sapiens | |||
| HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | |||
| MV4-11 | CVCL_0064 | Childhood acute monocytic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways. | |||||
